CrushSCI.com
96.2平均天数
80中位天数
31最短天数
205最长天数
712025发文量

Paper Review Records

全部论文审稿周期

20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

83 天

Perioperative Systemic Therapies for Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Network Meta-analysis

作者
Akihiro Matsukawa; Keiichiro Mori; Takafumi Yanagisawa; Keiichiro Miyajima; Yuki Enei; Wataru Fukuokaya; Kagenori Ito; Shunsuke Tsuzuki; Angelo Cormio; Marcin Miszczyk; Benjamin Pradere; Marco Moschini; Shahrokh F. Shariat; Jun Miki; Takahiro Kimura展开收起
作者单位
1. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; 2. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 3. Department of Urology, Università Politecnica Delle Marche, Ancona, Italy; 4. Collegium Medicum—Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland; 5. Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France; 6. Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffael, Milan, Italy; 7. Department of Urology, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran; 8. Department of Urology, Semmelweis University, Budapest, Hungary; 9. Department of Urology, The University of Texas Southwestern Medical Center, Dallas, USA; 10. Department of Urology, Weill Cornell Medical College, New York, USA; 11. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; 12. Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; 13. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; 14. Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran展开收起
PDF源文件 DOI 网页
36 天

Beyond Tumor-Agnostic TMB: Histology-Dependent Efficacy and Clinical Interpretation of Immune Checkpoint Inhibitors in TMB-High Solid Tumors

作者
Tamotsu Sagawa; Masahiro Hirakawa; Hiroyuki Nagashima; Koshi Fujikawa展开收起
作者单位
1. Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; 2. Division of Medical Oncology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan展开收起
PDF源文件 DOI 网页
52 天

Circulating Tumour DNA (ctDNA) as an Emerging Biomarker of Response in Early-Phase Oncology Drug Development: A Systematic Review

作者
Nadav Harel; Anthony Hamilton; Thomas C. T. Cope; William Harris; Yael Lefkovits; Mark Middleton; Jayesh Desai; Jeanne Tie展开收起
作者单位
1. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; 2. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia; 3. The Royal Melbourne Hospital, Melbourne, Australia; 4. Auckland City Hospital, Auckland, New Zealand; 5. Cabrini Health, Melbourne, Australia; 6. Department of Oncology, University of Oxford, Oxford, UK; 7. Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia展开收起
PDF源文件 DOI 网页
171 天

Clinical Significance of Comprehensive Genomic Profiling According to RAS and BRAF Status in Metastatic Colorectal Cancer

作者
Kazuki Ogawa; Hiroyuki Arai; Yuka Makino; Yohei Kubota; Yusuke Nagata; Yoshiki Horie; Hiroyuki Takeda; Kumiko Umemoto; Naoki Izawa; Yoshiaki Nakamura; Takayuki Yoshino; Yu Sunakawa展开收起
作者单位
1. Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki-shi, Japan; 2. Translational Research Support Office, National Cancer Center, Hospital East, Kashiwa, Japan; 3. Department of Oncology, University of Oxford, Oxford, UK; 4. Department of Gastrointestinal Oncology, National Cancer Center, Hospital East, Kashiwa, Japan展开收起
PDF源文件 DOI 网页
138 天

Imlunestrant as Monotherapy or in Combination with Abemaciclib in ER+, HER2− Advanced Breast Cancer: Chinese Subgroup Analysis of the Phase III Randomized EMBER-3 Study

作者
Xiaojia Wang; Jingwei Xu; Zhongsheng Tong; Tao Wu; Quchang Ouyang; Jian Liu; Yanxia Shi; Juan Huang; Hao Wang; Xinshuai Wang; Huihua Xiong; Jingjing Li; Li Zhou; Wanli Zhang; Qingyuan Zhang展开收起
作者单位
1. Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China; 2. Department of Breast Surgery, The Second Hospital of Jilin University, Changchun, China; 3. Department of Breast Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 4. Department of Oncology, Changde Hospital Affiliated to Xiangya School of Medicine, Central South University, The First People’s Hospital of Changde City, Changde, China; 5. Department of Breast Internal Medicine, Hunan Cancer Hospital, Changsha, China; 6. Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China; 7. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; 8. Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China; 9. Department of Breast, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China; 10. Department of Medical Oncology, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China; 11. Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China; 12. Eli Lilly and Company, Shanghai, China; 13. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China展开收起
PDF源文件 DOI 网页
41 天

Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

作者
Veronique Dieras; Giuseppe Curigliano; Miguel Martin; Florence Lerebours; Junji Tsurutani; Marie-France Savard; Katarzyna J. Jerzak; Xichun Hu; Ciara C. O’Sullivan; Eriko Tokunaga; Alicia Okines; Chiun-Sheng Huang; William Jacot; Joohyuk Sohn; Eduardo Cronemberger Silva; Volkmar Mueller; Shan Yang; Giovanna Granata; Qi Shen; Erika Hamilton展开收起
作者单位
1. Medical Oncology Department, Centre Eugène Marquis, Rennes, France; 2. European Institute of Oncology, IRCCS, Milan, Italy; 3. Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy; 4. Medical Oncology Service, Hospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain; 5. Institut Curie, Paris, France; 6. The Innovative Center of Translational Research and Clinical Science for Cancer Therapy, Showa Medical University Hospital, Tokyo, Japan; 7. Department of Medicine, The Ottawa Hospital Cancer Centre, Ottawa, Canada; 8. Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada; 9. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; 10. Department of Medical Oncology, Mayo Clinic, Rochester, USA; 11. Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; 12. Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK; 13. Institute of Cancer Research, London, UK; 14. Breast Care Center, National Taiwan University Hospital, Taipei, Taiwan; 15. Département d’Oncologie Médicale, Institut Regional du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, France; 16. Division of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea; 17. Medical Oncology, Centro Regional Integrado de Oncologia (CRIO), Fortaleza, Brazil; 18. Department of Gynecology and University Breast Center, Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; 19. Biostatistics, Pfizer Inc., Bothell, USA; 20. Oncology Late Stage Development, Pfizer AG, Zug, Switzerland; 21. Oncology, Research and Development, Pfizer Inc, Collegeville, USA; 22. Medical Oncology, Sarah Cannon Research Institute, Nashville, USA展开收起
PDF源文件 DOI 网页

FAQ

Targeted Oncology审稿要多久?

截至2026-11-18,CrushSCI 收录了 Targeted Oncology 的 20 篇完整审稿记录。最快一篇从收稿到录用用了 31 天(Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?,2026-04-20 收稿,2026-05-21 录用),最慢一篇用了 205 天;平均 96.2 天,中位数 80 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。